Results 41 to 50 of about 8,104 (211)

Tiotropium Bromide: An Update [PDF]

The Open Respiratory Medicine Journal, 2009
Tiotropium bromide is a once-daily inhaled anticholinergic bronchodilator. It works by blocking the muscarinic receptors in airway smooth muscle. Tiotropium has a wide therapeutic margin, due to its poor gastrointestinal absorption and its very low systemic bioavailability. The drug is mainly indicated in COPD patients.
openaire   +2 more sources

Tiotropium in children and adolescents with asthma [PDF]

Annals of Allergy, Asthma & Immunology, 2020
Asthma is a major cause of morbidity in children, despite the availability of various treatments. In adults, tiotropium-a long-acting muscarinic antagonist-as add-on therapy to an inhaled corticosteroid with or without a long-acting β2-agonist provides clinical benefit with a safety profile similar to placebo.To review published evidence on the ...
Kevin R, Murphy, Bradley E, Chipps
openaire   +2 more sources

The discovery and development of ensifentrine: A novel inhaled dual PDE3/4 inhibitor having ‘bifunctional’ bronchodilator and anti‐inflammatory activity

British Journal of Pharmacology, EarlyView.
Abstract Ensifentrine (formerly called RPL 554) is a novel, first in class, inhaled bifunctional dual PDE3/4 inhibitor for the treatment of chronic respiratory diseases. Ensifentrine exhibits both bronchodilation via PDE3 inhibition and anti‐inflammatory activity via PDE4 inhibition.
Clive Page
wiley   +1 more source

The evolving role of tiotropium in asthma

, 2017
Emma R McIvor,1 R Andrew McIvor2 1Queen’s University, Belfast, UK; 2Department of Medicine, McMaster University, Firestone Institute for Respiratory Health, Hamilton, Ontario, Canada Abstract: Tiotropium is a long-acting muscarinic antagonist (LAMA)
McIvor RA, R Andrew McIvor, McIvor ER, Emma McIvor   +3 more
core   +1 more source

Tiotropium in chronic obstructive pulmonary disease – a review of clinical development

Respiratory Research, 2020
Background Bronchodilators are the mainstay of pharmacological treatment in chronic obstructive pulmonary disease (COPD), and long-acting muscarinic antagonist (LAMA) monotherapy is recommended as initial treatment for Global Initiative for Chronic ...
Antonio Anzueto, Marc Miravitlles
doaj   +1 more source

Long‐Term Recurrence‐Free Outcome After Doxycycline Pleurodesis With Pulmonary Rehabilitation and Nutritional Support in an Underweight Patient With COPD: A Case Report

Respirology Case Reports, Volume 14, Issue 9, September 2026.
Recurrent secondary spontaneous pneumothorax (SSP) in chronic obstructive pulmonary disease (COPD) is associated with structural lung damage and underweight status. In this case, doxycycline pleurodesis combined with pulmonary rehabilitation and nutritional support was associated with sustained lung re‐expansion and a 22‐month recurrence‐free outcome ...
Kemas Rakhmat Notariza, Prasenohadi Pradono, Siti Chandra Widjanantie, Elfina Rachmi, Agus Dwi Susanto   +4 more
wiley   +1 more source

Long-term cost-effectiveness of the fixed-dose combination of tiotropium plus olodaterol based on the DYNAGITO trial results

International Journal of COPD, 2019
Martine Hoogendoorn,1 Isaac Corro Ramos,1 Michael Baldwin,2 Laura Luciani,3 Cecile Fabron,4 Bruno Detournay,4 Maureen PMH Rutten-van Mölken1,5 1institute for Medical Technology Assessment (iMTA), Erasmus University Rotterdam, Rotterdam, the ...
Hoogendoorn M, Corro Ramos I, Baldwin M, Luciani L, Fabron C, Detournay B, Rutten-van Mölken MPMH   +6 more
doaj  

The quantitative impact of metabolism‐inhibiting drugs on the occurrence of adverse drug reactions—A backward selection approach

British Journal of Clinical Pharmacology, Volume 92, Issue 7, Page 2203-2211, July 2026.
Abstract Aim The quantitative effect of several inhibitory drugs on the development of adverse drug reactions (ADRs) is currently difficult to estimate. Our aim was to identify metabolic pathways, which, when inhibited, increase the risk for certain ADRs, and to use this system to consider comedication at individual level. Methods Data of a prospective
Judith Berres, Justyna Wozniak, Hannah Fölsch, Anja Knueppel‐Ruppert, Verena Graeff, Andrea Kriegisch‐Stumpf, Harald Dormann, Julia C. Stingl, Katja S. Just   +8 more
wiley   +1 more source

Luteolin Glycoside From Dracocephalum moldavica L. Attenuates COPD by Modulating TLR4 Expression and Alveolar Cross‐Talk

Food Frontiers, Volume 7, Issue 4, July 2026.
Luteolin‐7‐O‐β‐d‐glucuronide mitigates CS‐induced COPD progression by promoting cytokine‐mediated functional cross‐talk between alveolar macrophages and epithelial cells. ABSTRACT Chronic obstructive pulmonary disease (COPD) is associated with inflammation of the airway and lung parenchyma with limited airflow due to continued exposure to harmful ...
Jianhu Jia, Tiantian Liu, Jiamin Huang, Na Zheng, Wei Wang, Song Wang, Wenjun Wang, Ghulam Jilany Khan, Jianhua Yang, Chenghui He, Fei Li, Hong Duan, Henggui Hu, Kefeng Zhai   +13 more
wiley   +1 more source

Anti-inflammatory effects of salmeterol/fluticasone, tiotropium/fluticasone or tiotropium in COPD [PDF]

European Respiratory Journal, 2009
The anti-inflammatory effects of salmeterol/fluticasone (SFP), tiotropium/fluticasone (Tio+FP) and tiotropium (Tio) alone were investigated on the inflammatory cells and mediators in sputum induced from chronic obstructive pulmonary disease patients.Subjects were either newly diagnosed or had not taken any medication for 3 months prior to the study ...
D-W, Perng, C-W, Tao, K-C, Su, C-C, Tsai, L-Y, Liu, Y-C, Lee   +5 more
openaire   +2 more sources